Morbidly "Healthy" Obese Are Not Metabolically Healthy but Less Metabolically Imbalanced Than Those with Type 2 Diabetes or Dyslipidemia

Obes Surg. 2015 Aug;25(8):1380-91. doi: 10.1007/s11695-014-1528-z.

Abstract

Background: We have investigated the differences between metabolically "healthy" morbidly obese patients and those with comorbidities.

Materials and methods: Thirty-two morbidly obese patients were divided by the absence ("healthy": DM-DL-) or presence of comorbidities (dyslipidemic: DM-DL+, or dyslipidemic and with type 2 diabetes: DM+DL+). We have studied various plasma parameters and gene expression adipose tissue, before and after gastric bypass.

Results: The group DM+DL+ tends to have lower values than the other two groups for anthropometric parameters. Regarding the satiety parameters, only leptin (p = 0.0024) showed a significant increase with comorbidities. Lipid parameters showed significant differences among groups, except for phospholipids and NEFA. For insulin resistance parameters, only glucose (p < 0.0001) was higher in DM+DL+ patients, but not insulin or homeostasis model assessment of insulin resistance (HOMA-IR). The gene expression of adiponectin, insulin receptor (INSR) and glucose receptor-4 (GLUT4), in the subcutaneous fat, decreased in all groups vs. a non-obese control. Interleukin-6 (IL6) and the inhibitor of plasminogen activator type 1 (PAI-1) genes decreased only in DM-DL+ and DM+DL+, but not in "healthy" patients. Leptin increased in all groups vs. the non-obese control. The visceral fat from DM+DL+ patients showed a sharp decrease in adiponectin, GLUT4, IL6 and PAI-1. All parameters mentioned above improved very significantly by surgery, independent of the occurrence of comorbidities.

Conclusions: The morbidly obese "healthy" individual is not really metabolically healthy, but morbidly obese individuals with diabetes and dyslipidemia are more metabolically imbalanced.

Publication types

  • Comparative Study

MeSH terms

  • Adiponectin / metabolism
  • Adult
  • Case-Control Studies
  • Diabetes Mellitus, Type 2 / epidemiology
  • Diabetes Mellitus, Type 2 / metabolism*
  • Diabetes Mellitus, Type 2 / surgery
  • Dyslipidemias / epidemiology
  • Dyslipidemias / metabolism*
  • Dyslipidemias / surgery
  • Female
  • Gastric Bypass
  • Glucose Transporter Type 4 / metabolism
  • Humans
  • Insulin / blood
  • Insulin Resistance
  • Interleukin-6 / metabolism
  • Intra-Abdominal Fat / metabolism
  • Intra-Abdominal Fat / pathology
  • Leptin / blood
  • Leptin / metabolism
  • Male
  • Middle Aged
  • Obesity, Metabolically Benign / epidemiology
  • Obesity, Metabolically Benign / metabolism*
  • Obesity, Metabolically Benign / surgery
  • Obesity, Morbid / epidemiology
  • Obesity, Morbid / metabolism*
  • Obesity, Morbid / surgery
  • Plasminogen Activator Inhibitor 1 / metabolism
  • Subcutaneous Fat / metabolism
  • Subcutaneous Fat / pathology
  • Young Adult

Substances

  • ADIPOQ protein, human
  • Adiponectin
  • Glucose Transporter Type 4
  • IL6 protein, human
  • Insulin
  • Interleukin-6
  • Leptin
  • Plasminogen Activator Inhibitor 1
  • SERPINE1 protein, human